Julie Ritchey

6.0k total citations
98 papers, 2.5k citations indexed

About

Julie Ritchey is a scholar working on Immunology, Oncology and Hematology. According to data from OpenAlex, Julie Ritchey has authored 98 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Immunology, 51 papers in Oncology and 50 papers in Hematology. Recurrent topics in Julie Ritchey's work include CAR-T cell therapy research (34 papers), Hematopoietic Stem Cell Transplantation (32 papers) and Immune Cell Function and Interaction (28 papers). Julie Ritchey is often cited by papers focused on CAR-T cell therapy research (34 papers), Hematopoietic Stem Cell Transplantation (32 papers) and Immune Cell Function and Interaction (28 papers). Julie Ritchey collaborates with scholars based in United States, Ireland and Australia. Julie Ritchey's co-authors include John F. DiPersio, Timothy L. Ratliff, Matthew Holt, Michael P. Rettig, Julie L. Prior, David Piwnica‐Worms, Jaebok Choi, Geoffrey L. Uy, Matthew Cooper and Pablo Ramírez and has published in prestigious journals such as Journal of Clinical Investigation, Nature Communications and Blood.

In The Last Decade

Julie Ritchey

94 papers receiving 2.5k citations

Peers

Countries citing papers authored by Julie Ritchey

Since Specialization

Citations

This map shows the geographic impact of Julie Ritchey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julie Ritchey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julie Ritchey more than expected).

Fields of papers citing papers by Julie Ritchey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julie Ritchey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julie Ritchey. The network helps show where Julie Ritchey may publish in the future.

Co-authorship network of co-authors of Julie Ritchey

This figure shows the co-authorship network connecting the top 25 collaborators of Julie Ritchey. A scholar is included among the top collaborators of Julie Ritchey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julie Ritchey. Julie Ritchey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Targeting CXCR4, VLA-4, and CXCR2 for hematopoietic stem cell mobilization 2024 ·Blood Advances ·Daniel Cancilla, Michael P. Rettig, Darja Karpova, (unknown), Megh Singh, Marvin J. Meyers, Peter Ruminski, Stephanie Christ, Ezhilarasi Chendamarai, Feng Gao, Leah Gehrs, Julie Ritchey, Michael J. Prinsen, John F. DiPersio	7
2	Rational Protein Engineering to Enhance MHC-Independent T-cell Receptors 2024 ·Cancer Discovery ·(unknown), (unknown), (unknown), (unknown), (unknown), John M. Warrington, Julie Ritchey, (unknown), Michael Slade, (unknown), John F. DiPersio, Alex S. Holehouse, Nathan Singh	5
3	Anti-myeloma efficacy of CAR-iNKT is enhanced with a long-acting IL-7, rhIL-7-hyFc 2023 ·Blood Advances ·Julie O’Neal, Matthew Cooper, Julie Ritchey, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Feng Gao, Byung Ha Lee, Donghoon Choi, Melissa M. Berrien-Elliott, Alice Y. Zhou, Todd A. Fehniger, (unknown), John F. DiPersio	20
4	Blinatumomab consolidation post–autologous stem cell transplantation in patients with diffuse large B-cell lymphoma 2023 ·Blood Advances ·Armin Ghobadi, (unknown), (unknown), Michael P. Rettig, Amanda F. Cashen, Leah Gehrs, Stephanie Christ, (unknown), Nicholas A. Wallace, Julie Ritchey, Neha Mehta–Shah, Peter Westervelt, Todd A. Fehniger, Brad S. Kahl, Nancy L. Bartlett, John F. DiPersio	6
5	Novel Small Molecule VLA-4 Inhibitors Optimized for Extended Hematopoietic and Progenitor Cell Mobilization 2023 ·Blood ·Peter Ruminski, Michael P. Rettig, Stephanie Christ, Megh Singh, Ezhilarasi Chendamarai, Leah Gehrs, Julie Ritchey, John F. DiPersio	1
6	An “Off-the-Shelf” CD2 Universal CAR-T Therapy Combined with a Long-Acting IL-7 for T-Cell Malignancies 2023 ·Blood ·Jingyu Xiang, Jessica M. Devenport, (unknown), Karl Staser, Michael P. Rettig, Miriam Kim, Julie O’Neal, Julie Ritchey, Feng Gao, Garrett R. Rettig, Rolf Turk, Alexandra A. Wolfarth, Byung Ha Lee, Matthew Cooper, John F. DiPersio	3
7	S100A9 upregulated by IFNGR signaling blockade functions as a novel GVHD suppressor without compromising GVL in mice 2022 ·Blood ·Sena Kim, (unknown), Boram Kim, Julie Ritchey, Kiran Vij, Julie L. Prior, Lynne Marsala, (unknown), Feng Gao, Samuel Achilefu, Matthew Cooper, John F. DiPersio, Jaebok Choi	1
8	Antibody-drug conjugates plus Janus kinase inhibitors enable MHC-mismatched allogeneic hematopoietic stem cell transplantation 2021 ·Journal of Clinical Investigation ·Stephen P. Persaud, Julie Ritchey, Sena Kim, (unknown), Peter Ruminski, Matthew Cooper, Michael P. Rettig, Jaebok Choi, John F. DiPersio	15
9	Baricitinib prevents GvHD by increasing Tregs via JAK3 and treats established GvHD by promoting intestinal tissue repair via EGFR 2021 ·Leukemia ·Sena Kim, (unknown), (unknown), Karl Staser, Kiran Vij, Srikanth Santhanam, Julie Ritchey, Sarah Peterson, Feng Gao, Matthew A. Ciorba, Matthew Cooper, John F. DiPersio, Jaebok Choi	16
10	VLA4-Targeted Nanoparticles Hijack Cell Adhesion–Mediated Drug Resistance to Target Refractory Myeloma Cells and Prolong Survival 2020 ·Clinical Cancer Research ·Francesca Fontana, Michael J. Scott, John S. Allen, Xiaoxia Yang, Grace Cui, Dipanjan Pan, (unknown), Mark A. Fiala, Julie O’Neal, (unknown), Julie Ritchey, Michael P. Rettig, (unknown), Steven Fletcher, Ravi Vij, John F. DiPersio, Gregory M. Lanza	19
11	Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host disease 2018 ·Leukemia ·Jaebok Choi, Matthew Cooper, Karl Staser, (unknown), Kiran Vij, Bing Wang, Lynne Marsala, (unknown), Julie Ritchey, Bader Alahmari, Samuel Achilefu, Ikuo Tsunoda, Mark A. Schroeder, John F. DiPersio	66
12	A Long-Acting Pharmacological Grade Interleukin-7 Molecule Logarithmically Accelerates Ucart Proliferation, Differentiation, and Tumor Killing 2018 ·Blood ·Matthew Cooper, Karl Staser, Julie Ritchey, (unknown), Byung Ha Lee, (unknown), John F. DiPersio	1
13	Selective targeting of histone modification fails to prevent graft versus host disease after hematopoietic cell transplantation 2018 ·PLoS ONE ·Bader Alahmari, Matthew Cooper, (unknown), Julie Ritchey, John F. DiPersio, Jaebok Choi	6
14	AMV564, a Bivalent Bispecific (2×2) CD33/CD3 T-Cell Engager, Is Active and Improves Survival in a Mouse Model of Acute Myeloid Leukemia 2018 ·Blood ·Linda Eissenberg, Julie Ritchey, Michael P. Rettig, Judith A. Fox, Jeanmarie Guenot, John F. DiPersio	4
15	Azacitidine Mitigates Graft-versus-Host Disease via Differential Effects on the Proliferation of T Effectors and Natural Regulatory T Cells In Vivo 2017 ·The Journal of Immunology ·Matthew Cooper, Jaebok Choi, Darja Karpova, Kiran Vij, Julie Ritchey, Mark A. Schroeder, John F. DiPersio	32
16	Factors affecting human T cell engraftment, trafficking, and associated xenogeneic graft-vs-host disease in NOD/SCID β2mnull mice 2007 ·Experimental Hematology ·Bruno Nervi, Michael P. Rettig, Julie Ritchey, Hanlin L. Wang, Gerhard Bauer, Jon Walker, Mark Bonyhadi, Ronald Berenson, Julie L. Prior, David Piwnica‐Worms, Jan A. Nolta, John F. DiPersio	52
17	Transduction and selection of human T cells with novel CD34/thymidine kinase chimeric suicide genes for the treatment of graft-versus-host disease 2003 ·Molecular Therapy ·Michael P. Rettig, Julie Ritchey, Todd E. Meyerrose, Jeffrey S. Haug, John F. DiPersio	26
18	Inhibition of Murine Prostate Tumor Growth and Activation of Immunoregulatory Cells With Recombinant Canarypox Viruses 2001 ·JNCI Journal of the National Cancer Institute ·Thomas S. Griffith, (unknown), Jianjun Paul Tian, Julie Ritchey, James Tartaglia, Inder Sehgal, Timothy C. Thompson, Weicheng Zhao, Timothy L. Ratliff	26
19	Effect of Canarypox Virus (ALVAC)-Mediated Cytokine Expression on Murine Prostate Tumor Growth 1997 ·JNCI Journal of the National Cancer Institute ·Mutsushi Kawakita, Geetha Rao, Julie Ritchey, David K. Ornstein, M’Liss A. Hudson, (unknown), (unknown), Peter A. Humphrey, James Tartaglia, Enzo Paoletti	51
20	Characterization of Soluble Fibronectin Binding to Bacille Calmette-Guerin 1989 ·Microbiology ·Jaber Aslanzadeh, Eric J. Brown, (unknown), Julie Ritchey, Timothy L. Ratliff	25

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact